SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TELK -- Telik, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (345)1/23/2003 10:32:15 AM
From: tuck  Respond to of 887
 
>>8:53AM Telik upgraded at Fulcrum (TELK) 12.25: Fulcrum upgrades to Buy from Neutral, saying the stock should gain momentum in 2003 for the following reasons: 1) expects co to start pivotal Phase III studies of their lead anticancer agent TLK-286 in Q1, 2) combination studies of TLK 286 could support use in a more lucrative "front-line" setting, 3) Phase IIb trials of TLK 199 in myelodysplasia are expected to begin in 2H03, and 4) "TRAP" drug discovery platform continues to provide a stream of new drug leads and the potential for new collaborations. Target is $17.<<

Cheers, Tuck



To: Miljenko Zuanic who wrote (345)3/27/2003 4:55:25 PM
From: keokalani'nui  Read Replies (1) | Respond to of 887
 
I read the article comparing tlk16998 and mrk's L7 in insulin resistant cells (both effective, different MOA, and potentially complementary) published in Diabetes--Vol 50--10/01.

For medicine's sake, anyone know how L7 is going?

As an aside, with 6x volume today you'd think there would be been >6.8% gain. Some sellers were ready.

Wilder


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News